Gilead increases Q2 revenue 13% and pumps up HCV R&D
This article was originally published in Scrip
Executive Summary
Gilead Sciences' reported second quarter 2012 revenue that beat analyst expectations on 26 July and said the company will initiate a Phase III clinical trial before the end of this year to test one of its hepatitis C virus (HCV) therapies in combination with another of its closely-watched HCV candidates before the end of the year.